



Clinical trial results:

A Single-Arm, Open-Label, Multicenter Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab in Previously Untreated Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma

Summary

EudraCT number	2015-001274-17
Trial protocol	DE SE IE FI GB NO AT BE IT
Global end of trial date	10 February 2020

Results information

Result version number	v1 (current)
This version publication date	21 May 2021
First version publication date	21 May 2021

Trial information

Trial identification

Sponsor protocol code	CA209-401
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 February 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	10 February 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To Determine the Safety, Tolerability and Efficacy of Nivolumab combined with Ipilimumab Followed by Nivolumab Monotherapy of Subjects with Stage III or IV Melanoma

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 74
Country: Number of subjects enrolled	Austria: 18
Country: Number of subjects enrolled	Belgium: 8
Country: Number of subjects enrolled	Sweden: 7
Country: Number of subjects enrolled	Switzerland: 76
Country: Number of subjects enrolled	Germany: 16
Country: Number of subjects enrolled	France: 107
Country: Number of subjects enrolled	Finland: 68
Country: Number of subjects enrolled	Ireland: 25
Country: Number of subjects enrolled	Italy: 100
Country: Number of subjects enrolled	Norway: 6
Country: Number of subjects enrolled	United Kingdom: 28
Worldwide total number of subjects	533
EEA total number of subjects	355

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	342
From 65 to 84 years	191
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

total treated participants = 533 subgroups of the total treated participants were based on Eastern Cooperative Oncology Group (ECOG) Performance Status (PS), Brain Metastasis, and Disease Subtype: ECOG PS0-1 = 477 ECOG PS2 = 55 Brain Metastasis = 42 Mucosal = 32 Ocular/Uveal = 64 Cutaneous = 365 Acral = 10 Other = 62

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Nivolumab + Ipilimumab
-----------	------------------------

Arm description:

Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240 mg) IV Q2W up to 21 months

Arm type	Experimental
Investigational medicinal product name	Nivolumab + Ipilimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Part 1: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Q3W Part 2: Nivolumab (3mg/kg or 240 mg) Q2W

Number of subjects in period 1	Nivolumab + Ipilimumab
Started	533
Completed	0
Not completed	533
Adverse event, serious fatal	26
Disease progression	153
Adverse Event unrelated to study drug	23
Participant withdrew consent	5
Study drug toxicity	201
Other Reasons	95
Maximum Clinical Benefit	7
Pregnancy	1
Participant no longer met study criteria	7

Lost to follow-up	1
Poor/non-compliance	1
Participant request to discontinue study treatment	13

Baseline characteristics

Reporting groups

Reporting group title	Nivolumab + Ipilimumab
-----------------------	------------------------

Reporting group description:

Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240 mg) IV Q2W up to 21 months

Reporting group values	Nivolumab + Ipilimumab	Total	
Number of subjects	533	533	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	342	342	
From 65-84 years	191	191	
85 years and over	0	0	
Age Continuous			
Units: Years			
median	59.0		
standard deviation	± 13.55	-	
Sex: Female, Male			
Units: Participants			
Female	217	217	
Male	316	316	
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	2	2	
Native Hawaiian or Other Pacific Islander	0	0	
Black or African American	0	0	
White	521	521	
More than one race	0	0	
Unknown or Not Reported	10	10	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	5	
Not Hispanic or Latino	515	515	
Unknown or Not Reported	13	13	

Subject analysis sets

Subject analysis set title	Nivolumab + Ipilimumab ECOG PS0-1
Subject analysis set type	Sub-group analysis
Subject analysis set description: Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 subgroup	
Subject analysis set title	Nivolumab + Ipilimumab ECOG PS2
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 subgroup	
Subject analysis set title	Nivolumab + Ipilimumab Brain Metastasis
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Brain Metastasis subgroup	
Subject analysis set title	Nivolumab + Ipilimumab Mucosal
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Mucosal	
Subject analysis set title	Nivolumab + Ipilimumab Ocular/Uveal
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Ocular/Uveal	
Subject analysis set title	Nivolumab + Ipilimumab Cutaneous
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Cutaneous	
Subject analysis set title	Nivolumab + Ipilimumab Acral
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Acral	
Subject analysis set title	Nivolumab + Ipilimumab Other
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Other	

Reporting group values	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Number of subjects	477	55	42
Age categorical Units: Subjects			
In utero	0	0	0

Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	308	34	30
From 65-84 years	169	21	12
85 years and over	0	0	0
Age Continuous			
Units: Years			
median	59.0	55.0	54.5
standard deviation	± 13.25	± 15.78	± 14.25
Sex: Female, Male			
Units: Participants			
Female	181	35	11
Male	296	20	31
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	466	54	41
More than one race	0	0	0
Unknown or Not Reported	10	0	1
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	5	0	0
Not Hispanic or Latino	459	55	41
Unknown or Not Reported	13	0	1

Reporting group values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous
Number of subjects	32	64	365
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	16	35	242
From 65-84 years	16	29	123
85 years and over	0	0	0
Age Continuous			
Units: Years			
median	64.0	63.0	58.0

standard deviation	± 13.21	± 13.67	± 13.37
--------------------	---------	---------	---------

Sex: Female, Male Units: Participants			
Female	21	29	134
Male	11	35	231
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	32	64	354
More than one race	0	0	0
Unknown or Not Reported	0	0	9
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	0	0	4
Not Hispanic or Latino	31	62	353
Unknown or Not Reported	1	2	8

Reporting group values	Nivolumab + Ipilimumab Acral	Nivolumab + Ipilimumab Other	
Number of subjects	10	62	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	5	44	
From 65-84 years	5	18	
85 years and over	0	0	
Age Continuous Units: Years			
median	67.5	55.5	
standard deviation	± 11.95	± 13.96	
Sex: Female, Male Units: Participants			
Female	5	28	
Male	5	34	
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	
Asian	0	0	
Native Hawaiian or Other Pacific Islander	0	0	

Black or African American	0	0	
White	10	61	
More than one race	0	0	
Unknown or Not Reported	0	1	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	0	
Not Hispanic or Latino	9	60	
Unknown or Not Reported	0	2	

End points

End points reporting groups

Reporting group title	Nivolumab + Ipilimumab
Reporting group description: Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240 mg) IV Q2W up to 21 months	
Subject analysis set title	Nivolumab + Ipilimumab ECOG PS0-1
Subject analysis set type	Sub-group analysis
Subject analysis set description: Part 1: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 subgroup	
Subject analysis set title	Nivolumab + Ipilimumab ECOG PS2
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 subgroup	
Subject analysis set title	Nivolumab + Ipilimumab Brain Metastasis
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Brain Metastasis subgroup	
Subject analysis set title	Nivolumab + Ipilimumab Mucosal
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Mucosal	
Subject analysis set title	Nivolumab + Ipilimumab Ocular/Uveal
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Ocular/Uveal	
Subject analysis set title	Nivolumab + Ipilimumab Cutaneous
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Cutaneous	
Subject analysis set title	Nivolumab + Ipilimumab Acral
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Acral	
Subject analysis set title	Nivolumab + Ipilimumab Other
Subject analysis set type	Sub-group analysis
Subject analysis set description: Nivolumab 1 mg/kg IV + Ipilimumab 3 mg/kg IV Q3W x 4 doses up to 3 months Then Part 2: Nivolumab (3mg/kg or 240mg) IV Q2W up to 21 months Participants were grouped in to Disease Subtype subgroup Other	

Primary: Incidence of Participants with High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events

End point title	Incidence of Participants with High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events ^[1]
-----------------	---

End point description:

Incidence of participants with high-grade (CTCAE v4.0 grade 3-5) treatment-related, select adverse events of potentially immune-mediated etiology including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity

End point type	Primary
----------------	---------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only summary statistics planned for this endpoint.

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Participants				
Pulmonary: Grade 3-4	7	7	0	0
Pulmonary: Grade 5	0	0	0	0
Gastrointestinal: Grade 3-4	83	79	4	5
Gastrointestinal: Grade 5	1	1	0	0
Skin: Grade 3-4	35	31	4	1
Skin: Grade 5	0	0	0	0
Renal: Grade 3-4	10	9	1	1
Renal: Grade 5	1	1	0	0
Hepatic: Grade 3-4	82	75	7	6
Hepatic: Grade 5	0	0	0	0
Endocrine: Grade 3-4	58	58	0	5
Endocrine: Grade 5	0	0	0	0
Hypersensitivity/Infusion Reaction: Grade 3-4	1	1	0	0
Hypersensitivity/Infusion Reaction: Grade 5	0	0	0	0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Participants				
Pulmonary: Grade 3-4	0	1	6	0
Pulmonary: Grade 5	0	0	0	0
Gastrointestinal: Grade 3-4	5	9	57	1
Gastrointestinal: Grade 5	1	0	0	0
Skin: Grade 3-4	3	7	20	1
Skin: Grade 5	0	0	0	0

Renal: Grade 3-4	0	1	8	0
Renal: Grade 5	0	0	1	0
Hepatic: Grade 3-4	2	17	56	1
Hepatic: Grade 5	0	0	0	0
Endocrine: Grade 3-4	2	6	43	1
Endocrine: Grade 5	0	0	0	0
Hypersensitivity/Infusion Reaction: Grade 3-4	0	0	1	0
Hypersensitivity/Infusion Reaction: Grade 5	0	0	0	0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Participants				
Pulmonary: Grade 3-4	0			
Pulmonary: Grade 5	0			
Gastrointestinal: Grade 3-4	11			
Gastrointestinal: Grade 5	0			
Skin: Grade 3-4	4			
Skin: Grade 5	0			
Renal: Grade 3-4	1			
Renal: Grade 5	0			
Hepatic: Grade 3-4	6			
Hepatic: Grade 5	0			
Endocrine: Grade 3-4	6			
Endocrine: Grade 5	0			
Hypersensitivity/Infusion Reaction: Grade 3-4	0			
Hypersensitivity/Infusion Reaction: Grade 5	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Participants with All High-Grade (Grades 3-5) Select Adverse Events

End point title	Incidence of Participants with All High-Grade (Grades 3-5) Select Adverse Events
-----------------	--

End point description:

Incidence of participants with high-grade (grade 3-5) select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, infusion-related, or hypersensitivity

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Participants				
Pulmonary: Grade 3-4	8	8	0	0
Gastrointestinal: Grade 3-4	87	83	4	5
Gastrointestinal: Grade 5	1	1	0	0
Skin: Grade 3-4	39	35	4	1
Renal: Grade 3-4	13	12	1	1
Renal: Grade 5	1	1	0	0
Hepatic: Grade 3-4	101	93	8	11
Hepatic: Grade 5	1	1	0	0
Hypersensitivity/Infusion Reaction: Grade 3-4	2	2	0	0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Participants				
Pulmonary: Grade 3-4	0	1	7	0
Gastrointestinal: Grade 3-4	5	9	61	1
Gastrointestinal: Grade 5	1	0	0	0
Skin: Grade 3-4	3	8	22	1
Renal: Grade 3-4	0	1	10	1
Renal: Grade 5	0	0	1	0
Hepatic: Grade 3-4	4	21	67	1
Hepatic: Grade 5	0	1	0	0
Hypersensitivity/Infusion Reaction: Grade 3-4	0	0	1	0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Participants				
Pulmonary: Grade 3-4	0			
Gastrointestinal: Grade 3-4	11			
Gastrointestinal: Grade 5	0			
Skin: Grade 3-4	5			

Renal: Grade 3-4	1			
Renal: Grade 5	0			
Hepatic: Grade 3-4	8			
Hepatic: Grade 5	0			
Hypersensitivity/Infusion Reaction: Grade 3-4	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Median Time to Onset (Grades 3-4) of Select Adverse Events

End point title	Median Time to Onset (Grades 3-4) of Select Adverse Events
-----------------	--

End point description:

Median time to onset (grades 3-4) of select adverse events including pulmonary, gastrointestinal (GI), skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity for all treated participants with at least one select adverse event from the category

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533 ^[2]	477 ^[3]	55 ^[4]	42 ^[5]
Units: Days				
median (full range (min-max))				
Pulmonary	51.5 (12 to 783)	51.5 (12 to 783)	99999 (99999 to 99999)	99999 (99999 to 99999)
Gastrointestinal (GI)	49.0 (7 to 582)	49.0 (7 to 582)	61.0 (8 to 91)	83.0 (35 to 543)
Skin	32.0 (4 to 670)	35.0 (4 to 404)	17.5 (7 to 670)	14.0 (14 to 14)
Renal	52.5 (6 to 540)	43.0 (6 to 223)	540.0 (540 to 540)	106.0 (106 to 106)
Hepatic	63.0 (5 to 724)	63.0 (5 to 724)	63.0 (13 to 83)	64.0 (41 to 724)
Endocrine	75 (7 to 369)	75.0 (7 to 369)	99999 (99999 to 99999)	67.0 (25 to 130)
Hypersensitivity/Infusion Reaction	291.5 (22 to 561)	291.5 (22 to 561)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[2] - Pulmonary=8 GI=88 Skin=39 Renal=14 Hepatic=102 Endocrine=59 Hypersensitivity/Infusion Reaction=2

[3] - Pulmonary=8 GI=84 Skin=35 Renal=13 Hepatic=94 Endocrine=59 Hypersensitivity/Infusion Reaction=2

[4] - Pulmonary=0 GI=4 Skin=4 Renal=1 Hepatic=8 Endocrine=0 Hypersensitivity/Infusion Reaction=0

[5] - Pulmonary=0 GI=42 Skin=1 Renal=1 Hepatic=11 Endocrine=5 Hypersensitivity/Infusion Reaction=0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32 ^[6]	64 ^[7]	365 ^[8]	10 ^[9]
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)	51.0 (51 to 51)	52.0 (12 to 783)	99999 (99999 to 99999)
Gastrointestinal (GI)	42.5 (27 to 543)	39.0 (20 to 95)	49.0 (7 to 582)	7.0 (7 to 7)
Skin	48.0 (8 to 69)	36.5 (14 to 127)	17.5 (4 to 670)	89.0 (89 to 89)
Renal	99999 (99999 to 99999)	23.0 (23 to 23)	106.0 (14 to 540)	16.0 (16 to 16)
Hepatic	139.0 (22 to 475)	64.0 (16 to 111)	62.0 (5 to 588)	101.0 (101 to 101)
Endocrine	153.0 (102 to 204)	70.0 (26 to 98)	71.5 (7 to 369)	114.0 (114 to 114)
Hypersensitivity/Infusion Reaction	99999 (99999 to 99999)	99999 (99999 to 99999)	22.0 (22 to 22)	99999 (99999 to 99999)

Notes:

[6] - Pulmonary=0 GI=6 Skin=3 Renal=0 Hepatic=4 Endocrine=2 Hypersensitivity/Infusion Reaction=0

[7] - Pulmonary=1 GI=9 Skin=8 Renal=1 Hepatic=22 Endocrine=6 Hypersensitivity/Infusion Reaction=0

[8] - Pulmonary=7 GI=61 Skin=22 Renal=11 Hepatic=67 Endocrine=44 Hypersensitivity/Infusion Reaction=1

[9] - Pulmonary=0 GI=10 Skin=1 Renal=1 Hepatic=1 Endocrine=1 Hypersensitivity/Infusion Reaction=1

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62 ^[10]			
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)			
Gastrointestinal (GI)	79.0 (8 to 281)			
Skin	100.0 (10 to 338)			
Renal	6.0 (6 to 6)			
Hepatic	80.0 (8 to 724)			
Endocrine	39.5 (16 to 115)			
Hypersensitivity/Infusion Reaction	561.0 (561 to 561)			

Notes:

[10] - Pulmonary=0 GI=11 Skin=5 Renal=1 Hepatic=0 Endocrine=6 Hypersensitivity/Infusion Reaction=1

Statistical analyses

No statistical analyses for this end point

Secondary: Median Time to Resolution (Grades 3-4) of Select Adverse Events

End point title	Median Time to Resolution (Grades 3-4) of Select Adverse Events
-----------------	---

End point description:

Median time to resolution (Grades 3-4) of select adverse events including pulmonary, gastrointestinal (GI), skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity of all treated participants with at least one select adverse event from the category

End point type Secondary

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533 ^[11]	477 ^[12]	55 ^[13]	42 ^[14]
Units: Days				
median (full range (min-max))				
Pulmonary	19.0 (5 to 64)	19.0 (5 to 64)	99999 (99999 to 99999)	99999 (99999 to 99999)
Gastrointestinal (GI)	22.0 (2 to 684)	22.0 (2 to 684)	99999 (99999 to 99999)	107.5 (18 to 666)
Skin	24.0 (4 to 690)	24.0 (4 to 690)	20.0 (10 to 186)	67.0 (67 to 67)
Renal	19 (3 to 66)	23.0 (3 to 66)	11.0 (11 to 11)	7.0 (7 to 7)
Hepatic	42.0 (1 to 889)	38.0 (1 to 889)	67.0 (3 to 225)	17.5 (2 to 285)
Endocrine	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)
Hypersensitivity/Infusion Reaction	4.5 (2 to 7)	4.5 (2 to 7)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[11] - Pulmonary=8 GI=88 Skin=39 Renal=14 Hepatic=102 Endocrine=59 Hypersensitivity/Infusion Reaction=2

[12] - Pulmonary=8 GI=84 Skin=35 Renal=13 Hepatic=94 Endocrine=59 Hypersensitivity/Infusion Reaction=2

[13] - Pulmonary=0 GI=4 Skin=4 Renal=1 Hepatic=8 Endocrine=0 Hypersensitivity/Infusion Reaction=0

[14] - Pulmonary=0 GI=5 Skin=1 Renal=1 Hepatic=11 Endocrine=5 Hypersensitivity/Infusion Reaction=0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32 ^[15]	64 ^[16]	365 ^[17]	10 ^[18]
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)	6.0 (6 to 6)	30.0 (5 to 64)	99999 (99999 to 99999)
Gastrointestinal (GI)	25.0 (6 to 437)	14.0 (6 to 183)	23.0 (2 to 684)	5.0 (5 to 5)
Skin	8.0 (5 to 44)	17.5 (4 to 690)	24.0 (8 to 455)	15.0 (15 to 15)
Renal	99999 (99999 to 99999)	23.0 (23 to 23)	11.0 (3 to 60)	99999 (99999 to 99999)
Hepatic	126.0 (1 to 625)	55.0 (1 to 612)	30.0 (2 to 889)	29.0 (29 to 29)
Endocrine	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

Hypersensitivity/Infusion Reaction	99999 (99999 to 99999)	99999 (99999 to 99999)	2.0 (2 to 2)	99999 (99999 to 99999)
------------------------------------	------------------------	------------------------	--------------	------------------------

Notes:

[15] - Pulmonary=0 GI=6 Skin=3 Renal=0 Hepatic=4 Endocrine=2 Hypersensitivity/Infusion Reaction=0

[16] - Pulmonary=1 GI=9 Skin=8 Renal=1 Hepatic=22 Endocrine=6 Hypersensitivity/Infusion Reaction=0

[17] - Pulmonary=7 GI=61 Skin=22 Renal=11 Hepatic=67 Endocrine=44 Hypersensitivity/Infusion Reaction=1

[18] - Pulmonary=0 GI=1 Skin=1 Renal=1 Hepatic=1 Endocrine=1 Hypersensitivity/Infusion Reaction=0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62 ^[19]			
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)			
Gastrointestinal (GI)	12.0 (4 to 214)			
Skin	28.0 (4 to 287)			
Renal	66.0 (66 to 66)			
Hepatic	117.0 (15 to 285)			
Endocrine	99999 (99999 to 99999)			
Hypersensitivity/Infusion Reaction	7.0 (7 to 7)			

Notes:

[19] - Pulmonary=0 GI=11 Skin=5 Renal=1 Hepatic=8 Endocrine=6 Hypersensitivity/Infusion Reaction=1

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Resolution of an Adverse Event (AE)

End point title	Time to Resolution of an Adverse Event (AE)
End point description:	
Resolution of an adverse event (AE) is defined as a participant experiencing complete resolution or improvement to the baseline of any grade AE including pulmonary, gastrointestinal (GI), skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity all treated participants with at least one select adverse event from the category	
End point type	Secondary
End point timeframe:	
From first dose to 30 days after last dose (up to approximately 37 months)	

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533 ^[20]	447 ^[21]	55 ^[22]	42 ^[23]
Units: Days				
median (full range (min-max))				
Pulmonary	35.0 (6 to 738)	43.0 (6 to 738)	7.5 (7 to 8)	99999 (99999 to 99999)
Gastrointestinal (GI)	18.0 (1 to 1016)	18.0 (1 to 1016)	12.0 (1 to 468)	36.0 (1 to 720)
Skin	89.0 (1 to 1175)	88.0 (1 to 1175)	99999 (99999 to 99999)	257.0 (1 to 1011)
Renal	56.0 (2 to 904)	56.0 (2 to 904)	11.0 (11 to 11)	5.5 (2 to 100)
Hepatic	44.0 (1 to 1008)	43.0 (1 to 1008)	80.5 (3 to 225)	20.5 (3 to 1008)
Endocrine	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)
Hypersensitivity/Infusion Reaction	1.0 (1 to 7)	1.0 (1 to 7)	1.0 (1 to 1)	99999 (99999 to 99999)

Notes:

[20] - Pulmonary=28 GI=252 Skin=319 Renal=43 Hepatic=185 Endocrine=242

Hypersensitivity/Infusion Reaction=8

[21] - Pulmonary=26 GI=236 Skin=296 Renal=42 Hepatic=173 Endocrine=231

Hypersensitivity/Infusion Reaction=7

[22] - Pulmonary=2 GI=16 Skin=23 Renal=1 Hepatic=12 Endocrine=11 Hypersensitivity/Infusion Reaction=1

[23] - Pulmonary=2 GI=14 Skin=23 Renal=4 Hepatic=16 Endocrine=20 Hypersensitivity/Infusion Reaction=0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32 ^[24]	64 ^[25]	365 ^[26]	10 ^[27]
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)	19.0 (6 to 62)	43.0 (7 to 738)	99999 (99999 to 99999)
Gastrointestinal (GI)	14.0 (1 to 527)	14.0 (1 to 183)	19.0 (1 to 1016)	5.0 (1 to 22)
Skin	84.0 (5 to 1055)	33.5 (4 to 775)	102.0 (1 to 1175)	46.0 (15 to 625)
Renal	9.5 (4 to 15)	27.5 (23 to 32)	56.0 (2 to 904)	99999 (99999 to 99999)
Hepatic	97.0 (1 to 650)	34.0 (1 to 612)	37.0 (3 to 912)	129.0 (31 to 129)
Endocrine	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)
Hypersensitivity/Infusion Reaction	99999 (99999 to 99999)	99999 (99999 to 99999)	1.0 (1 to 7)	99999 (99999 to 99999)

Notes:

[24] - Pulmonary=2 GI=13 Skin=17 Renal=2 Hepatic=7 Endocrine=15 Hypersensitivity/Infusion Reaction=0

[25] - Pulmonary=3 GI=31 Skin=34 Renal=2 Hepatic=35 Endocrine=29 Hypersensitivity/Infusion Reaction=0

[26] - Pulmonary=21 GI=175 Skin=228 Renal=34 Hepatic=128 Endocrine=166 Hypersensitivity/Infusion Reaction=5

[27] - Pulmonary=0 GI=6 Skin=8 Renal=1 Hepatic=2 Endocrine=5 Hypersensitivity/Infusion Reaction=0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62 ^[28]			
Units: Days				
median (full range (min-max))				
Pulmonary	99999 (99999 to 99999)			
Gastrointestinal (GI)	36.0 (2 to 645)			
Skin	59.5 (2 to 952)			
Renal	99999 (99999 to 99999)			
Hepatic	29.0 (8 to 1008)			
Endocrine	99999 (99999 to 99999)			
Hypersensitivity/Infusion Reaction	1.0 (1 to 7)			

Notes:

[28] - Pulmonary=2 GI=27 Skin=32 Renal=4 Hepatic=13 Endocrine=27 Hypersensitivity/Infusion Reaction=3

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
Overall survival is defined from the time of first dosing date to the date of death. A participant who has not died will be censored at the last known date alive	
End point type	Secondary
End point timeframe:	
Up to approximately 37 months	

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Months				
median (confidence interval 95%)	99999 (33.91 to 99999)	99999 (34.76 to 99999)	11.01 (7.23 to 99999)	99999 (99999 to 99999)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab
------------------	---------------------------	---------------------------	---------------------------	---------------------------

	Mucosal	Ocular/Uveal	Cutaneous	Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Months				
median (confidence interval 95%)	12.55 (3.78 to 33.91)	15.21 (10.41 to 21.42)	99999 (99999 to 99999)	20.83 (1.15 to 99999)

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Months				
median (confidence interval 95%)	34.76 (16.69 to 99999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Participants with Adverse Events

End point title	Incidence of Participants with Adverse Events
End point description:	
The assessment of safety is measured by the incidence of participants who experienced any grade of adverse events (AEs), treatment-related AEs, serious adverse events (SAEs), and deaths	
End point type	Secondary
End point timeframe:	
From first dose to 30 days after last dose (up to approximately 37 months)	

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Participants				
Adverse Events (AEs)	533	477	55	42
Treatment-Related AEs	484	444	40	33
Serious Adverse Events (SAEs)	356	324	31	31
Deaths	199	169	29	13

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
------------------	--------------------------------------	---	--	------------------------------------

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Participants				
Adverse Events (AEs)	32	64	365	10
Treatment-Related AEs	26	61	332	8
Serious Adverse Events (SAEs)	26	40	238	9
Deaths	20	41	107	6

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Participants				
Adverse Events (AEs)	62			
Treatment-Related AEs	35			
Serious Adverse Events (SAEs)	43			
Deaths	25			

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Participants with Select Adverse Events

End point title	Incidence of Participants with Select Adverse Events
-----------------	--

End point description:

The assessment of safety is measured by the incidence of participants who experienced any grade of select adverse events including pulmonary, gastrointestinal, skin, renal, hepatic, endocrine, infusion-related, or hypersensitivity

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Participants				
Pulmonary	28	26	2	2
Gastrointestinal	252	236	16	14
Skin	319	296	23	23
Renal	43	42	1	4
Hepatic	185	173	12	16
Endocrine	242	231	11	20

Hypersensitivity/Infusion Reaction	8	7	1	0
------------------------------------	---	---	---	---

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Participants				
Pulmonary	2	3	21	0
Gastrointestinal	13	31	175	6
Skin	17	34	228	8
Renal	2	2	34	1
Hepatic	7	35	128	2
Endocrine	15	29	166	5
Hypersensitivity/Infusion Reaction	0	0	5	0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Participants				
Pulmonary	2			
Gastrointestinal	27			
Skin	32			
Renal	4			
Hepatic	13			
Endocrine	27			
Hypersensitivity/Infusion Reaction	3			

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Participants with Laboratory Abnormalities - Liver

End point title	Incidence of Participants with Laboratory Abnormalities - Liver
-----------------	---

End point description:

Safety assessment is measured by the incidence of participants who experienced a liver laboratory abnormality in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Upper Limit of Normal (ULN) of all treated participants with at least one on-treatment measurement of the corresponding laboratory parameter

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	490	442	48	37
Units: Participants				
ALT OR AST > 3XULN	113	106	7	11
ALT OR AST > 5XULN	75	69	6	4
ALT OR AST > 10XULN	30	27	3	0
ALT OR AST > 20XULN	12	11	1	0
TOTAL BILIRUBIN > 2XULN	12	12	0	1
ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	1	1	0	0
ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	4	4	0	0

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	29	56	338	10
Units: Participants				
ALT OR AST > 3XULN	7	21	72	2
ALT OR AST > 5XULN	5	13	48	1
ALT OR AST > 10XULN	2	4	22	0
ALT OR AST > 20XULN	1	2	7	0
TOTAL BILIRUBIN > 2XULN	0	3	8	0
ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	0	0	1	0
ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	0	0	4	0

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	57			
Units: Participants				
ALT OR AST > 3XULN	11			
ALT OR AST > 5XULN	8			
ALT OR AST > 10XULN	2			
ALT OR AST > 20XULN	2			
TOTAL BILIRUBIN > 2XULN	1			
ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	0			

ALT/AST ELEVATED>3XULN;BILIRUBIN>2XULN	0			
---	---	--	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of Participants with Laboratory Abnormalities - Thyroid

End point title	Incidence of Participants with Laboratory Abnormalities - Thyroid
-----------------	---

End point description:

Safety assessment is measured by the incidence of participants who experienced a thyroid laboratory abnormality in Free T3 (FT3), Free T4 (FT4), Lower Limit of Normal (LLN) of all treated participants with at least one on-treatment TSH measurement

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to 30 days after last dose (up to approximately 37 months)

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	449	410	39	35
Units: Participants				
TSH > ULN	130	123	7	12
TSH > ULN WITH TSH <= ULN AT BASELINE	113	108	5	11
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN	80	76	4	8
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN	37	35	2	3
TSH > ULN WITH FT3/FT4 TEST MISSING	26	25	1	2
TSH < LLN	178	169	9	14
TSH <LLN WITH TSH >= LLN AT BASELINE	168	159	9	14
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN	101	98	3	7
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN	59	53	6	5
TSH < LLN WITH FT3/FT4 TEST MISSING	26	25	1	2

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
------------------	--------------------------------------	---	--	------------------------------------

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	26	49	313	10
Units: Participants				
TSH > ULN	8	12	91	4
TSH > ULN WITH TSH ≤ ULN AT BASELINE	6	10	79	3
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN	5	6	55	2
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN	1	4	27	2
TSH > ULN WITH FT3/FT4 TEST MISSING	2	2	21	0
TSH < LLN	11	23	124	4
TSH <LLN WITH TSH ≥ LLN AT BASELINE	11	21	116	4
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN	8	12	72	2
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN	3	8	40	1
TSH < LLN WITH FT3/FT4 TEST MISSING	0	4	19	1

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	51			
Units: Participants				
TSH > ULN	15			
TSH > ULN WITH TSH ≤ ULN AT BASELINE	15			
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN	12			
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN	3			
TSH > ULN WITH FT3/FT4 TEST MISSING	1			
TSH < LLN	16			
TSH <LLN WITH TSH ≥ LLN AT BASELINE	16			
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN	7			
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN	7			
TSH < LLN WITH FT3/FT4 TEST MISSING	2			

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
End point description:	
Objective response rate is defined as the percentage of participants with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of all treated participants	
End point type	Secondary
End point timeframe:	
Up to approximately 37 months	

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Percentage				
number (confidence interval 95%)	44.5 (40.2 to 48.8)	46.1 (41.6 to 50.7)	30.9 (19.0 to 44.8)	52.4 (36.4 to 68.0)

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Percentage				
number (confidence interval 95%)	43.8 (26.4 to 62.3)	9.4 (3.5 to 19.3)	51.2 (46.0 to 56.5)	30.0 (6.7 to 65.2)

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Percentage				
number (confidence interval 95%)	43.5 (31.0 to 56.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
End point description:	
Progression free survival per investigator assessment is defined as radiological evidence of progression, significant clinical symptomatic progression, or the need to introduce a non-study drug therapy.	

End point type	Secondary
End point timeframe:	
Up to approximately 37 months	

End point values	Nivolumab + Ipilimumab	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Subject group type	Reporting group	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	533	477	55	42
Units: Months				
median (confidence interval 95%)	4.96 (3.45 to 6.77)	5.45 (3.78 to 7.69)	2.46 (1.77 to 3.75)	3.35 (1.81 to 99999)

End point values	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous	Nivolumab + Ipilimumab Acral
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	64	365	10
Units: Months				
median (confidence interval 95%)	2.94 (2.53 to 8.74)	2.83 (2.73 to 4.63)	6.77 (4.67 to 10.45)	2.56 (1.15 to 8.48)

End point values	Nivolumab + Ipilimumab Other			
Subject group type	Subject analysis set			
Number of subjects analysed	62			
Units: Months				
median (confidence interval 95%)	5.22 (2.76 to 27.27)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from start of first treatment dose up to 30 days post last treatment dose.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Nivolumab + Ipilimumab ECOG PS0-1
-----------------------	-----------------------------------

Reporting group description:

Subjects received nivolumab 1 milligram/kilogram (mg/kg) intravenously (i.v) with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1 subgroup.

Reporting group title	Nivolumab + Ipilimumab ECOG PS2
-----------------------	---------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2 subgroup.

Reporting group title	Nivolumab + Ipilimumab Brain Metastasis
-----------------------	---

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Brain Metastasis subgroup.

Reporting group title	Nivolumab + Ipilimumab Mucosal
-----------------------	--------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Disease Subtype subgroup Mucosal.

Reporting group title	Nivolumab + Ipilimumab Ocular/Uveal
-----------------------	-------------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Disease Subtype subgroup Ocular/Uveal.

Reporting group title	Nivolumab + Ipilimumab Cutaneous
-----------------------	----------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Disease Subtype subgroup Cutaneous.

Reporting group title	Nivolumab + Ipilimumab Acral
-----------------------	------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Disease Subtype subgroup Acral.

Reporting group title	Nivolumab + Ipilimumab Other
-----------------------	------------------------------

Reporting group description:

Subjects received nivolumab 1 mg/kg i.v with a combination of ipilimumab 3 mg/kg every 3 weeks up to 12 weeks and subjects who entered after the implementation of amendment 4 were administered iv nivolumab 240 mg up to 24 months. Subjects were grouped in to Disease Subtype subgroup Other.

Serious adverse events	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Total subjects affected by serious adverse events			
subjects affected / exposed	355 / 477 (74.42%)	33 / 55 (60.00%)	32 / 42 (76.19%)
number of deaths (all causes)	169	29	13
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic myeloid leukaemia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	86 / 477 (18.03%)	17 / 55 (30.91%)	15 / 42 (35.71%)
occurrences causally related to treatment / all	0 / 102	0 / 19	0 / 16
deaths causally related to treatment / all	0 / 51	0 / 15	0 / 6
Metastases to liver			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic malignant melanoma			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal squamous cell carcinoma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vein collapse			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	1 / 477 (0.21%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis superficial			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	4 / 7	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyserositis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	18 / 477 (3.77%)	1 / 55 (1.82%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	13 / 20	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Non-Cardiac chest pain			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 477 (0.00%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular stent thrombosis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune endocrine disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Eosinophilic granulomatosis with polyangiitis			

subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Metrorrhagia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysmenorrhoea			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	5 / 477 (1.05%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	2 / 6	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	6 / 477 (1.26%)	1 / 55 (1.82%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	0 / 7	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	10 / 477 (2.10%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	8 / 10	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	6 / 477 (1.26%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Pulmonary haematoma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Immune-Mediated pneumonitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organic brain syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	8 / 477 (1.68%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	8 / 8	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical condition abnormal subjects affected / exposed	4 / 477 (0.84%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Liver function test increased subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	5 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cells urine positive subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-Reactive protein increased subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Clavicle fracture			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fever			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			

subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myocardial infarction			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	1 / 477 (0.21%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Stress cardiomyopathy			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			

subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neuropathy			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autonomic neuropathy			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cubital tunnel syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Guillain-Barre syndrome			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	7 / 477 (1.47%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	6 / 7	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intercostal neuralgia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lesion			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paresis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osmotic demyelination syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraplegia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplastic anaemia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Autoimmune pancytopenia			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Autoimmune uveitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diplopia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Photopsia			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	5 / 477 (1.05%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune colitis			
subjects affected / exposed	13 / 477 (2.73%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	19 / 19	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			

subjects affected / exposed	51 / 477 (10.69%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	65 / 67	2 / 2	1 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	35 / 477 (7.34%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	33 / 40	2 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry mouth			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			

subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 477 (0.21%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth haemorrhage			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	4 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic failure			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	3 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune pancreatitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated enterocolitis			
subjects affected / exposed	9 / 477 (1.89%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	10 / 10	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatobiliary disorders			
Autoimmune hepatitis			

subjects affected / exposed	16 / 477 (3.35%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	20 / 20	2 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disease			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	7 / 477 (1.47%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	8 / 9	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			

subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-Induced liver injury			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated hepatitis			
subjects affected / exposed	17 / 477 (3.56%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	20 / 20	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis allergic			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug reaction with eosinophilia and systemic symptoms			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichen planus			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pemphigoid			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriasis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	5 / 477 (1.05%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	4 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	5 / 5	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	10 / 477 (2.10%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	4 / 10	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Nephritis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 477 (0.21%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated renal disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Adrenal insufficiency			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	6 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenocortical insufficiency acute			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	8 / 477 (1.68%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	8 / 8	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophysitis			
subjects affected / exposed	24 / 477 (5.03%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	26 / 26	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypopituitarism			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocytic hypophysitis			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	6 / 6	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary adrenal insufficiency			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis acute			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated hyperthyroidism			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	2 / 477 (0.42%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw cyst			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatic disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle disorder			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyarthritis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar osteitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis viral			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 6	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	5 / 477 (1.05%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 5	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic arthritis streptococcal			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cns ventriculitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			

subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangitis			
subjects affected / exposed	0 / 477 (0.00%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia klebsiella			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	6 / 477 (1.26%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	5 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			

subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	5 / 477 (1.05%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketoacidosis			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	3 / 3	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			

subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 1 diabetes mellitus			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 32 (87.50%)	47 / 64 (73.44%)	257 / 365 (70.41%)
number of deaths (all causes)	20	41	107
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic myeloid leukaemia			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	11 / 32 (34.38%)	16 / 64 (25.00%)	59 / 365 (16.16%)
occurrences causally related to treatment / all	0 / 14	0 / 19	0 / 67
deaths causally related to treatment / all	0 / 8	0 / 12	0 / 33
Metastases to liver			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic malignant melanoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal squamous cell carcinoma			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vein collapse			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral venous disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis superficial			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	5 / 365 (1.37%)
occurrences causally related to treatment / all	0 / 0	2 / 2	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
General physical health deterioration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyserositis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	2 / 32 (6.25%)	2 / 64 (3.13%)	14 / 365 (3.84%)
occurrences causally related to treatment / all	0 / 2	1 / 2	11 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-Cardiac chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vascular stent thrombosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytokine release syndrome			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune endocrine disorder			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Eosinophilic granulomatosis with polyangiitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Metrorrhagia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysmenorrhoea			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	6 / 365 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	5 / 365 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	7 / 365 (1.92%)
occurrences causally related to treatment / all	0 / 0	2 / 2	5 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	5 / 365 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary haematoma			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Immune-Mediated pneumonitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organic brain syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 32 (3.13%)	3 / 64 (4.69%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	1 / 1	3 / 3	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical condition abnormal			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oxygen saturation decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	4 / 365 (1.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	5 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cells urine positive			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-Reactive protein increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural fever			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Atrial fibrillation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Myocardial infarction			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Stress cardiomyopathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune neuropathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autonomic neuropathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cubital tunnel syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Guillain-Barre syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	7 / 365 (1.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	6 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intercostal neuralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lesion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cognitive disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paresis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osmostic demyelination syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraplegia			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplastic anaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Autoimmune pancytopenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphopenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Autoimmune uveitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diplopia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Photopsia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal detachment			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal pain upper			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune colitis			
subjects affected / exposed	1 / 32 (3.13%)	2 / 64 (3.13%)	7 / 365 (1.92%)
occurrences causally related to treatment / all	2 / 2	4 / 4	9 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic gastritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	3 / 32 (9.38%)	4 / 64 (6.25%)	39 / 365 (10.68%)
occurrences causally related to treatment / all	4 / 4	6 / 6	48 / 50
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 32 (3.13%)	5 / 64 (7.81%)	30 / 365 (8.22%)
occurrences causally related to treatment / all	1 / 1	5 / 5	28 / 35
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry mouth			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal toxicity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth haemorrhage			

subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	4 / 365 (1.10%)
occurrences causally related to treatment / all	0 / 0	1 / 2	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic failure			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	1 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autoimmune pancreatitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated enterocolitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	8 / 365 (2.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	9 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	13 / 365 (3.56%)
occurrences causally related to treatment / all	0 / 0	2 / 2	18 / 18
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hepatitis			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	1 / 1	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis acute			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disease			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	3 / 32 (9.38%)	1 / 64 (1.56%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	5 / 5	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-Induced liver injury			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated hepatitis			

subjects affected / exposed	0 / 32 (0.00%)	3 / 64 (4.69%)	11 / 365 (3.01%)
occurrences causally related to treatment / all	0 / 0	3 / 3	14 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis allergic			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug eruption			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichen planus			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pemphigoid			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriasis			

subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash maculo-papular			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	1 / 1	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	7 / 365 (1.92%)
occurrences causally related to treatment / all	0 / 1	1 / 1	3 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Haematuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated renal disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	4 / 365 (1.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adrenocortical insufficiency acute			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthyroidism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	8 / 365 (2.19%)
occurrences causally related to treatment / all	0 / 0	0 / 0	8 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophysitis			
subjects affected / exposed	1 / 32 (3.13%)	5 / 64 (7.81%)	15 / 365 (4.11%)
occurrences causally related to treatment / all	1 / 1	5 / 5	17 / 17
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypopituitarism			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocytic hypophysitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	6 / 365 (1.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	6 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Primary adrenal insufficiency			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis acute			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-Mediated hyperthyroidism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			

subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw cyst			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathological fracture			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			

subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatic disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyarthritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial cyst			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar osteitis			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis viral			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	4 / 365 (1.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis infectious			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumococcal infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	3 / 64 (4.69%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyoderma			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection viral			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	5 / 365 (1.37%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic arthritis streptococcal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal bacteraemia			

subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bacteraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cns ventriculitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphangitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia klebsiella			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	5 / 365 (1.37%)
occurrences causally related to treatment / all	1 / 1	0 / 0	4 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	4 / 365 (1.10%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ketoacidosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Nivolumab + Ipilimumab Acral	Nivolumab + Ipilimumab Other	
-------------------------------	---------------------------------	---------------------------------	--

Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	47 / 62 (75.81%)	
number of deaths (all causes)	6	25	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic myeloid leukaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm progression			
subjects affected / exposed	3 / 10 (30.00%)	14 / 62 (22.58%)	
occurrences causally related to treatment / all	0 / 4	0 / 17	
deaths causally related to treatment / all	0 / 3	0 / 10	
Metastases to liver			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic malignant melanoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm malignant			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal squamous cell carcinoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vasculitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vein collapse			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral venous disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthermia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyserositis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-Cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular stent thrombosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytokine release syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemophagocytic lymphohistiocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune endocrine disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eosinophilic granulomatosis with polyangiitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast			

disorders			
Metrorrhagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysmenorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleurisy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-Mediated pneumonitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleuritic pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Organic brain syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical condition abnormal			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	

Liver function test increased subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oxygen saturation decreased subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cells urine positive subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-Reactive protein increased subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clavicle fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infusion related reaction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural fever			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrioventricular block			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stress cardiomyopathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ataxia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune neuropathy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autonomic neuropathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Carpal tunnel syndrome			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrospinal fluid leakage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cubital tunnel syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Guillain-Barre syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intercostal neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Petit mal epilepsy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Central nervous system lesion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cognitive disorder			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paresis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osmotic demyelination syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paraplegia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aplastic anaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune pancytopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphadenopathy			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Autoimmune uveitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Photopsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal detachment			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune colitis			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences causally related to treatment / all	1 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	7 / 62 (11.29%)	
occurrences causally related to treatment / all	0 / 0	9 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ulcerative			

subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry mouth			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal toxicity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mouth haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal hernia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Autoimmune pancreatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-Mediated enterocolitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Autoimmune hepatitis			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholestasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis acute			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatocellular injury			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatotoxicity			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug-Induced liver injury			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-Mediated hepatitis			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dermatitis allergic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug eruption			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug reaction with eosinophilia and systemic symptoms			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erythema			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lichen planus			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pemphigoid			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Haematuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nephritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-Mediated renal disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adrenocortical insufficiency acute			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthyroidism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophysitis			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences causally related to treatment / all	0 / 0	3 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypopituitarism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocytic hypophysitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Primary adrenal insufficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thyroiditis acute			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-Mediated hyperthyroidism			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bursitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc protrusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Jaw cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatic disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscle disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthrititis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovial cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abscess limb			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alveolar osteitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Campylobacter gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Encephalitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enteritis infectious			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal viral infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis aseptic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumococcal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural cellulitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyoderma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhinovirus infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic arthritis streptococcal			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound infection staphylococcal			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cns ventriculitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphangitis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meningitis bacterial			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oral candidiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia klebsiella			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			

subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ketoacidosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 1 diabetes mellitus			

subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Nivolumab + Ipilimumab ECOG PS0-1	Nivolumab + Ipilimumab ECOG PS2	Nivolumab + Ipilimumab Brain Metastasis
Total subjects affected by non-serious adverse events			
subjects affected / exposed	463 / 477 (97.06%)	51 / 55 (92.73%)	40 / 42 (95.24%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	4 / 477 (0.84%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	4	1	0
Hepatic neoplasm			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Malignant neoplasm progression			
subjects affected / exposed	11 / 477 (2.31%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences (all)	11	2	2
Vascular disorders			
Hypertension			
subjects affected / exposed	30 / 477 (6.29%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences (all)	35	0	2
Hot flush			
subjects affected / exposed	18 / 477 (3.77%)	0 / 55 (0.00%)	3 / 42 (7.14%)
occurrences (all)	21	0	4

Lymphoedema			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	3	0	0
Lymphorrhoea			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	2	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	88 / 477 (18.45%)	14 / 55 (25.45%)	9 / 42 (21.43%)
occurrences (all)	128	16	12
Chills			
subjects affected / exposed	27 / 477 (5.66%)	1 / 55 (1.82%)	2 / 42 (4.76%)
occurrences (all)	31	1	2
Fatigue			
subjects affected / exposed	182 / 477 (38.16%)	5 / 55 (9.09%)	13 / 42 (30.95%)
occurrences (all)	255	6	20
Influenza like illness			
subjects affected / exposed	41 / 477 (8.60%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	61	0	2
Oedema peripheral			
subjects affected / exposed	41 / 477 (8.60%)	4 / 55 (7.27%)	3 / 42 (7.14%)
occurrences (all)	47	4	5
Pyrexia			
subjects affected / exposed	116 / 477 (24.32%)	19 / 55 (34.55%)	7 / 42 (16.67%)
occurrences (all)	149	25	11
Gait disturbance			
subjects affected / exposed	2 / 477 (0.42%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	2	1	0
Hyperthermia			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Malaise			
subjects affected / exposed	3 / 477 (0.63%)	3 / 55 (5.45%)	0 / 42 (0.00%)
occurrences (all)	8	3	0
Non-Cardiac chest pain			

subjects affected / exposed occurrences (all)	5 / 477 (1.05%) 5	0 / 55 (0.00%) 0	1 / 42 (2.38%) 1
Reproductive system and breast disorders			
Rectocele			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			
subjects affected / exposed	2 / 477 (0.42%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	3	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	106 / 477 (22.22%)	10 / 55 (18.18%)	7 / 42 (16.67%)
occurrences (all)	131	11	7
Dyspnoea			
subjects affected / exposed	62 / 477 (13.00%)	5 / 55 (9.09%)	3 / 42 (7.14%)
occurrences (all)	76	5	5
Epistaxis			
subjects affected / exposed	8 / 477 (1.68%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	8	0	1
Haemoptysis			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	3	0	0
Oropharyngeal pain			
subjects affected / exposed	23 / 477 (4.82%)	2 / 55 (3.64%)	0 / 42 (0.00%)
occurrences (all)	24	2	0
Pleural effusion			
subjects affected / exposed	6 / 477 (1.26%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	6	1	0
Pulmonary embolism			
subjects affected / exposed	13 / 477 (2.73%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	13	0	0
Pulmonary pain			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			

Insomnia			
subjects affected / exposed	60 / 477 (12.58%)	6 / 55 (10.91%)	5 / 42 (11.90%)
occurrences (all)	72	7	5
Anxiety			
subjects affected / exposed	23 / 477 (4.82%)	0 / 55 (0.00%)	3 / 42 (7.14%)
occurrences (all)	24	0	3
Depression			
subjects affected / exposed	10 / 477 (2.10%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences (all)	10	0	2
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	98 / 477 (20.55%)	12 / 55 (21.82%)	9 / 42 (21.43%)
occurrences (all)	129	15	14
Amylase increased			
subjects affected / exposed	41 / 477 (8.60%)	4 / 55 (7.27%)	2 / 42 (4.76%)
occurrences (all)	50	9	2
Aspartate aminotransferase increased			
subjects affected / exposed	84 / 477 (17.61%)	8 / 55 (14.55%)	8 / 42 (19.05%)
occurrences (all)	105	14	10
Blood alkaline phosphatase increased			
subjects affected / exposed	29 / 477 (6.08%)	2 / 55 (3.64%)	3 / 42 (7.14%)
occurrences (all)	32	3	4
Lipase increased			
subjects affected / exposed	78 / 477 (16.35%)	7 / 55 (12.73%)	11 / 42 (26.19%)
occurrences (all)	112	11	17
Weight decreased			
subjects affected / exposed	54 / 477 (11.32%)	4 / 55 (7.27%)	4 / 42 (9.52%)
occurrences (all)	59	4	4
Blood bilirubin increased			
subjects affected / exposed	16 / 477 (3.35%)	4 / 55 (7.27%)	1 / 42 (2.38%)
occurrences (all)	31	6	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	17 / 477 (3.56%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	18	1	1
Blood potassium decreased			

subjects affected / exposed	6 / 477 (1.26%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	7	1	1
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	9 / 477 (1.89%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	9	2	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	12 / 477 (2.52%)	1 / 55 (1.82%)	3 / 42 (7.14%)
occurrences (all)	14	1	3
Blood uric acid increased			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	4	0	1
C-Reactive protein increased			
subjects affected / exposed	13 / 477 (2.73%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	14	1	1
Gamma-Glutamyltransferase increased			
subjects affected / exposed	30 / 477 (6.29%)	3 / 55 (5.45%)	5 / 42 (11.90%)
occurrences (all)	31	3	5
Haemoglobin decreased			
subjects affected / exposed	4 / 477 (0.84%)	3 / 55 (5.45%)	0 / 42 (0.00%)
occurrences (all)	5	5	0
Hepatic enzyme increased			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	2	0	0
Liver function test increased			
subjects affected / exposed	4 / 477 (0.84%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	5	0	0
Neutrophil count decreased			
subjects affected / exposed	5 / 477 (1.05%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	5	1	0
Thyroxine increased			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	3	0	0
Transaminases increased			

subjects affected / exposed occurrences (all)	14 / 477 (2.94%) 16	0 / 55 (0.00%) 0	2 / 42 (4.76%) 2
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	3 / 477 (0.63%) 4	1 / 55 (1.82%) 1	0 / 42 (0.00%) 0
Cardiac disorders Atrial tachycardia subjects affected / exposed occurrences (all) Tachycardia subjects affected / exposed occurrences (all)	2 / 477 (0.42%) 2 16 / 477 (3.35%) 17	0 / 55 (0.00%) 0 3 / 55 (5.45%) 3	0 / 42 (0.00%) 0 0 / 42 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all) Dizziness subjects affected / exposed occurrences (all) Paraesthesia subjects affected / exposed occurrences (all) Somnolence subjects affected / exposed occurrences (all)	113 / 477 (23.69%) 145 27 / 477 (5.66%) 31 26 / 477 (5.45%) 29 4 / 477 (0.84%) 4	9 / 55 (16.36%) 10 0 / 55 (0.00%) 0 1 / 55 (1.82%) 2 3 / 55 (5.45%) 3	14 / 42 (33.33%) 19 4 / 42 (9.52%) 5 2 / 42 (4.76%) 2 0 / 42 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all) Lymphadenopathy subjects affected / exposed occurrences (all) Lymphopenia subjects affected / exposed occurrences (all)	58 / 477 (12.16%) 78 7 / 477 (1.47%) 8 7 / 477 (1.47%) 7	9 / 55 (16.36%) 10 0 / 55 (0.00%) 0 1 / 55 (1.82%) 1	3 / 42 (7.14%) 3 1 / 42 (2.38%) 1 0 / 42 (0.00%) 0

Eye disorders			
Eyelash discolouration			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	3	0	0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	76 / 477 (15.93%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences (all)	105	3	7
Abdominal pain upper			
subjects affected / exposed	35 / 477 (7.34%)	4 / 55 (7.27%)	3 / 42 (7.14%)
occurrences (all)	41	5	3
Constipation			
subjects affected / exposed	83 / 477 (17.40%)	7 / 55 (12.73%)	12 / 42 (28.57%)
occurrences (all)	100	7	15
Diarrhoea			
subjects affected / exposed	214 / 477 (44.86%)	15 / 55 (27.27%)	13 / 42 (30.95%)
occurrences (all)	383	25	22
Dry mouth			
subjects affected / exposed	51 / 477 (10.69%)	1 / 55 (1.82%)	2 / 42 (4.76%)
occurrences (all)	58	1	2
Nausea			
subjects affected / exposed	151 / 477 (31.66%)	11 / 55 (20.00%)	10 / 42 (23.81%)
occurrences (all)	210	15	14
Vomiting			
subjects affected / exposed	85 / 477 (17.82%)	8 / 55 (14.55%)	9 / 42 (21.43%)
occurrences (all)	112	11	14
Abdominal distension			
subjects affected / exposed	13 / 477 (2.73%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	13	0	0
Colitis			
subjects affected / exposed	29 / 477 (6.08%)	3 / 55 (5.45%)	1 / 42 (2.38%)
occurrences (all)	37	3	1
Dyspepsia			
subjects affected / exposed	19 / 477 (3.98%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	24	1	0
Dysphagia			

subjects affected / exposed	12 / 477 (2.52%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	13	0	1
Haematemesis			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	3	0	0
Mouth ulceration			
subjects affected / exposed	7 / 477 (1.47%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	7	0	0
Stomatitis			
subjects affected / exposed	28 / 477 (5.87%)	4 / 55 (7.27%)	2 / 42 (4.76%)
occurrences (all)	31	4	2
Hepatobiliary disorders			
Hepatocellular injury			
subjects affected / exposed	17 / 477 (3.56%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	21	1	2
Hypertransaminasaemia			
subjects affected / exposed	2 / 477 (0.42%)	2 / 55 (3.64%)	1 / 42 (2.38%)
occurrences (all)	2	2	1
Liver tenderness			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	139 / 477 (29.14%)	11 / 55 (20.00%)	12 / 42 (28.57%)
occurrences (all)	180	15	14
Rash			
subjects affected / exposed	80 / 477 (16.77%)	7 / 55 (12.73%)	6 / 42 (14.29%)
occurrences (all)	92	8	7
Rash macular			
subjects affected / exposed	32 / 477 (6.71%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences (all)	36	3	2
Rash maculo-papular			

subjects affected / exposed	61 / 477 (12.79%)	6 / 55 (10.91%)	5 / 42 (11.90%)
occurrences (all)	84	7	8
Rash pruritic			
subjects affected / exposed	32 / 477 (6.71%)	2 / 55 (3.64%)	0 / 42 (0.00%)
occurrences (all)	43	4	0
Vitiligo			
subjects affected / exposed	62 / 477 (13.00%)	9 / 55 (16.36%)	7 / 42 (16.67%)
occurrences (all)	70	9	7
Acne			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	3	0	1
Alopecia			
subjects affected / exposed	17 / 477 (3.56%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	21	1	1
Dry skin			
subjects affected / exposed	28 / 477 (5.87%)	1 / 55 (1.82%)	2 / 42 (4.76%)
occurrences (all)	30	1	2
Eczema			
subjects affected / exposed	23 / 477 (4.82%)	0 / 55 (0.00%)	5 / 42 (11.90%)
occurrences (all)	27	0	6
Erythema			
subjects affected / exposed	27 / 477 (5.66%)	0 / 55 (0.00%)	6 / 42 (14.29%)
occurrences (all)	27	0	6
Hair colour changes			
subjects affected / exposed	9 / 477 (1.89%)	0 / 55 (0.00%)	2 / 42 (4.76%)
occurrences (all)	9	0	2
Hyperhidrosis			
subjects affected / exposed	20 / 477 (4.19%)	2 / 55 (3.64%)	1 / 42 (2.38%)
occurrences (all)	21	2	1
Nail dystrophy			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Plantar erythema			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Renal and urinary disorders			

Dysuria subjects affected / exposed occurrences (all)	2 / 477 (0.42%) 2	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	98 / 477 (20.55%) 102	2 / 55 (3.64%) 2	7 / 42 (16.67%) 9
Hypophysitis subjects affected / exposed occurrences (all)	29 / 477 (6.08%) 30	3 / 55 (5.45%) 3	3 / 42 (7.14%) 3
Hypothyroidism subjects affected / exposed occurrences (all)	118 / 477 (24.74%) 129	6 / 55 (10.91%) 7	8 / 42 (19.05%) 10
Adrenal insufficiency subjects affected / exposed occurrences (all)	23 / 477 (4.82%) 25	2 / 55 (3.64%) 2	1 / 42 (2.38%) 1
Immune-Mediated hyperthyroidism subjects affected / exposed occurrences (all)	1 / 477 (0.21%) 1	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Thyroiditis subjects affected / exposed occurrences (all)	14 / 477 (2.94%) 14	1 / 55 (1.82%) 1	0 / 42 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	77 / 477 (16.14%) 108	2 / 55 (3.64%) 2	5 / 42 (11.90%) 9
Back pain subjects affected / exposed occurrences (all)	50 / 477 (10.48%) 60	4 / 55 (7.27%) 5	7 / 42 (16.67%) 8
Musculoskeletal pain subjects affected / exposed occurrences (all)	32 / 477 (6.71%) 36	1 / 55 (1.82%) 1	2 / 42 (4.76%) 3
Myalgia subjects affected / exposed occurrences (all)	37 / 477 (7.76%) 45	4 / 55 (7.27%) 4	3 / 42 (7.14%) 3
Pain in extremity			

subjects affected / exposed	33 / 477 (6.92%)	3 / 55 (5.45%)	2 / 42 (4.76%)
occurrences (all)	45	3	3
Haematoma muscle			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Joint swelling			
subjects affected / exposed	8 / 477 (1.68%)	0 / 55 (0.00%)	1 / 42 (2.38%)
occurrences (all)	8	0	1
Limb mass			
subjects affected / exposed	1 / 477 (0.21%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal chest pain			
subjects affected / exposed	10 / 477 (2.10%)	1 / 55 (1.82%)	0 / 42 (0.00%)
occurrences (all)	10	1	0
Neck pain			
subjects affected / exposed	19 / 477 (3.98%)	1 / 55 (1.82%)	1 / 42 (2.38%)
occurrences (all)	20	1	1
Pain in jaw			
subjects affected / exposed	2 / 477 (0.42%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	2	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	51 / 477 (10.69%)	1 / 55 (1.82%)	6 / 42 (14.29%)
occurrences (all)	69	1	11
Conjunctivitis			
subjects affected / exposed	17 / 477 (3.56%)	1 / 55 (1.82%)	3 / 42 (7.14%)
occurrences (all)	18	1	4
Infection			
subjects affected / exposed	3 / 477 (0.63%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	4	0	0
Influenza			
subjects affected / exposed	12 / 477 (2.52%)	0 / 55 (0.00%)	3 / 42 (7.14%)
occurrences (all)	12	0	3
Oral candidiasis			
subjects affected / exposed	21 / 477 (4.40%)	2 / 55 (3.64%)	3 / 42 (7.14%)
occurrences (all)	21	2	3

Oral fungal infection subjects affected / exposed occurrences (all)	3 / 477 (0.63%) 3	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	13 / 477 (2.73%) 13	1 / 55 (1.82%) 1	0 / 42 (0.00%) 0
Paronychia subjects affected / exposed occurrences (all)	5 / 477 (1.05%) 6	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Post procedural cellulitis subjects affected / exposed occurrences (all)	1 / 477 (0.21%) 3	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Tongue fungal infection subjects affected / exposed occurrences (all)	2 / 477 (0.42%) 2	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Tooth abscess subjects affected / exposed occurrences (all)	3 / 477 (0.63%) 4	0 / 55 (0.00%) 0	0 / 42 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	25 / 477 (5.24%) 29	1 / 55 (1.82%) 1	2 / 42 (4.76%) 3
Urinary tract infection subjects affected / exposed occurrences (all)	24 / 477 (5.03%) 27	3 / 55 (5.45%) 3	2 / 42 (4.76%) 2
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	113 / 477 (23.69%) 142	7 / 55 (12.73%) 8	12 / 42 (28.57%) 19
Hypokalaemia subjects affected / exposed occurrences (all)	43 / 477 (9.01%) 59	4 / 55 (7.27%) 5	6 / 42 (14.29%) 7
Diabetes mellitus subjects affected / exposed occurrences (all)	8 / 477 (1.68%) 9	1 / 55 (1.82%) 1	1 / 42 (2.38%) 1
Hyperglycaemia			

subjects affected / exposed	17 / 477 (3.56%)	2 / 55 (3.64%)	5 / 42 (11.90%)
occurrences (all)	20	2	6
Hypocalcaemia			
subjects affected / exposed	10 / 477 (2.10%)	2 / 55 (3.64%)	1 / 42 (2.38%)
occurrences (all)	12	3	2
Hyponatraemia			
subjects affected / exposed	19 / 477 (3.98%)	2 / 55 (3.64%)	2 / 42 (4.76%)
occurrences (all)	23	2	3
Hypophosphataemia			
subjects affected / exposed	12 / 477 (2.52%)	0 / 55 (0.00%)	0 / 42 (0.00%)
occurrences (all)	16	0	0

Non-serious adverse events	Nivolumab + Ipilimumab Mucosal	Nivolumab + Ipilimumab Ocular/Uveal	Nivolumab + Ipilimumab Cutaneous
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 32 (93.75%)	61 / 64 (95.31%)	354 / 365 (96.99%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences (all)	2	0	3
Hepatic neoplasm			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Malignant neoplasm progression			
subjects affected / exposed	1 / 32 (3.13%)	4 / 64 (6.25%)	6 / 365 (1.64%)
occurrences (all)	1	4	6
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 32 (3.13%)	6 / 64 (9.38%)	19 / 365 (5.21%)
occurrences (all)	1	7	23
Hot flush			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	12 / 365 (3.29%)
occurrences (all)	2	1	14
Lymphoedema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1
Lymphorrhoea			

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 32 (18.75%)	13 / 64 (20.31%)	66 / 365 (18.08%)
occurrences (all)	6	14	103
Chills			
subjects affected / exposed	4 / 32 (12.50%)	2 / 64 (3.13%)	19 / 365 (5.21%)
occurrences (all)	4	2	23
Fatigue			
subjects affected / exposed	9 / 32 (28.13%)	19 / 64 (29.69%)	136 / 365 (37.26%)
occurrences (all)	15	29	185
Influenza like illness			
subjects affected / exposed	3 / 32 (9.38%)	3 / 64 (4.69%)	31 / 365 (8.49%)
occurrences (all)	6	3	48
Oedema peripheral			
subjects affected / exposed	4 / 32 (12.50%)	8 / 64 (12.50%)	26 / 365 (7.12%)
occurrences (all)	6	8	30
Pyrexia			
subjects affected / exposed	7 / 32 (21.88%)	13 / 64 (20.31%)	95 / 365 (26.03%)
occurrences (all)	9	15	118
Gait disturbance			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1
Hyperthermia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	4 / 365 (1.10%)
occurrences (all)	0	1	5
Non-Cardiac chest pain			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences (all)	2	0	3
Reproductive system and breast disorders			

Rectocele subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 3	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	13 / 64 (20.31%) 16	82 / 365 (22.47%) 100
Dyspnoea subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 6	9 / 64 (14.06%) 12	44 / 365 (12.05%) 52
Epistaxis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 64 (1.56%) 1	6 / 365 (1.64%) 6
Haemoptysis subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	2 / 365 (0.55%) 2
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	4 / 64 (6.25%) 4	13 / 365 (3.56%) 13
Pleural effusion subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 64 (0.00%) 0	5 / 365 (1.37%) 5
Pulmonary embolism subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	2 / 64 (3.13%) 2	7 / 365 (1.92%) 7
Pulmonary pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	4 / 64 (6.25%) 4	55 / 365 (15.07%) 68
Anxiety			

subjects affected / exposed	1 / 32 (3.13%)	4 / 64 (6.25%)	15 / 365 (4.11%)
occurrences (all)	1	4	16
Depression			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	9 / 365 (2.47%)
occurrences (all)	0	0	9
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	5 / 32 (15.63%)	21 / 64 (32.81%)	73 / 365 (20.00%)
occurrences (all)	7	26	96
Amylase increased			
subjects affected / exposed	1 / 32 (3.13%)	6 / 64 (9.38%)	34 / 365 (9.32%)
occurrences (all)	1	9	43
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 32 (12.50%)	17 / 64 (26.56%)	63 / 365 (17.26%)
occurrences (all)	4	23	81
Blood alkaline phosphatase increased			
subjects affected / exposed	3 / 32 (9.38%)	6 / 64 (9.38%)	20 / 365 (5.48%)
occurrences (all)	3	6	23
Lipase increased			
subjects affected / exposed	4 / 32 (12.50%)	8 / 64 (12.50%)	64 / 365 (17.53%)
occurrences (all)	8	8	96
Weight decreased			
subjects affected / exposed	4 / 32 (12.50%)	6 / 64 (9.38%)	44 / 365 (12.05%)
occurrences (all)	4	6	46
Blood bilirubin increased			
subjects affected / exposed	0 / 32 (0.00%)	4 / 64 (6.25%)	16 / 365 (4.38%)
occurrences (all)	0	6	31
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 32 (0.00%)	3 / 64 (4.69%)	12 / 365 (3.29%)
occurrences (all)	0	3	13
Blood potassium decreased			
subjects affected / exposed	2 / 32 (6.25%)	1 / 64 (1.56%)	3 / 365 (0.82%)
occurrences (all)	2	1	4
Blood thyroid stimulating hormone decreased			

subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	6 / 365 (1.64%)
occurrences (all)	0	3	6
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 32 (0.00%)	3 / 64 (4.69%)	8 / 365 (2.19%)
occurrences (all)	0	3	10
Blood uric acid increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	2	0	0
C-Reactive protein increased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	9 / 365 (2.47%)
occurrences (all)	1	0	10
Gamma-Glutamyltransferase increased			
subjects affected / exposed	2 / 32 (6.25%)	1 / 64 (1.56%)	27 / 365 (7.40%)
occurrences (all)	2	1	28
Haemoglobin decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	6 / 365 (1.64%)
occurrences (all)	0	0	8
Hepatic enzyme increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1
Liver function test increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	3 / 365 (0.82%)
occurrences (all)	0	0	4
Neutrophil count decreased			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	3 / 365 (0.82%)
occurrences (all)	1	1	3
Thyroxine increased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences (all)	0	0	2
Transaminases increased			
subjects affected / exposed	0 / 32 (0.00%)	5 / 64 (7.81%)	7 / 365 (1.92%)
occurrences (all)	0	5	9
Injury, poisoning and procedural complications			

Fall subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 64 (0.00%) 0	1 / 365 (0.27%) 1
Cardiac disorders Atrial tachycardia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 64 (1.56%) 1	0 / 365 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	1 / 64 (1.56%) 1	15 / 365 (4.11%) 16
Nervous system disorders Headache subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5	13 / 64 (20.31%) 18	91 / 365 (24.93%) 115
Dizziness subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	2 / 64 (3.13%) 2	18 / 365 (4.93%) 22
Paraesthesia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	3 / 64 (4.69%) 3	24 / 365 (6.58%) 28
Somnolence subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 64 (1.56%) 1	5 / 365 (1.37%) 5
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	7 / 64 (10.94%) 9	39 / 365 (10.68%) 51
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	5 / 365 (1.37%) 6
Lymphopenia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 64 (0.00%) 0	6 / 365 (1.64%) 6
Eye disorders Eyelash discolouration subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	2 / 365 (0.55%) 2

Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	3 / 32 (9.38%)	10 / 64 (15.63%)	55 / 365 (15.07%)
occurrences (all)	3	13	77
Abdominal pain upper			
subjects affected / exposed	3 / 32 (9.38%)	10 / 64 (15.63%)	23 / 365 (6.30%)
occurrences (all)	3	14	26
Constipation			
subjects affected / exposed	7 / 32 (21.88%)	7 / 64 (10.94%)	66 / 365 (18.08%)
occurrences (all)	9	7	79
Diarrhoea			
subjects affected / exposed	13 / 32 (40.63%)	28 / 64 (43.75%)	158 / 365 (43.29%)
occurrences (all)	19	46	293
Dry mouth			
subjects affected / exposed	2 / 32 (6.25%)	5 / 64 (7.81%)	37 / 365 (10.14%)
occurrences (all)	2	7	41
Nausea			
subjects affected / exposed	8 / 32 (25.00%)	24 / 64 (37.50%)	111 / 365 (30.41%)
occurrences (all)	14	34	148
Vomiting			
subjects affected / exposed	5 / 32 (15.63%)	7 / 64 (10.94%)	69 / 365 (18.90%)
occurrences (all)	10	8	90
Abdominal distension			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	7 / 365 (1.92%)
occurrences (all)	1	1	7
Colitis			
subjects affected / exposed	2 / 32 (6.25%)	5 / 64 (7.81%)	20 / 365 (5.48%)
occurrences (all)	3	5	26
Dyspepsia			
subjects affected / exposed	1 / 32 (3.13%)	4 / 64 (6.25%)	12 / 365 (3.29%)
occurrences (all)	1	6	14
Dysphagia			
subjects affected / exposed	3 / 32 (9.38%)	1 / 64 (1.56%)	7 / 365 (1.92%)
occurrences (all)	3	1	8
Haematemesis			

subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
Haemorrhoidal haemorrhage subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	1 / 365 (0.27%) 1
Mouth ulceration subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 64 (0.00%) 0	5 / 365 (1.37%) 5
Stomatitis subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	2 / 64 (3.13%) 2	24 / 365 (6.58%) 27
Hepatobiliary disorders Hepatocellular injury subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	2 / 64 (3.13%) 2	11 / 365 (3.01%) 14
Hypertransaminasaemia subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 64 (0.00%) 0	2 / 365 (0.55%) 2
Liver tenderness subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 64 (0.00%) 0	0 / 365 (0.00%) 0
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	11 / 32 (34.38%) 11	13 / 64 (20.31%) 24	106 / 365 (29.04%) 133
Rash subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	8 / 64 (12.50%) 8	63 / 365 (17.26%) 75
Rash macular subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	2 / 64 (3.13%) 2	24 / 365 (6.58%) 26
Rash maculo-papular subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 5	6 / 64 (9.38%) 7	50 / 365 (13.70%) 69
Rash pruritic			

subjects affected / exposed	3 / 32 (9.38%)	1 / 64 (1.56%)	29 / 365 (7.95%)
occurrences (all)	3	1	42
Vitiligo			
subjects affected / exposed	2 / 32 (6.25%)	1 / 64 (1.56%)	58 / 365 (15.89%)
occurrences (all)	3	1	63
Acne			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences (all)	0	0	2
Alopecia			
subjects affected / exposed	2 / 32 (6.25%)	1 / 64 (1.56%)	11 / 365 (3.01%)
occurrences (all)	2	1	15
Dry skin			
subjects affected / exposed	2 / 32 (6.25%)	2 / 64 (3.13%)	21 / 365 (5.75%)
occurrences (all)	2	2	22
Eczema			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	18 / 365 (4.93%)
occurrences (all)	3	0	21
Erythema			
subjects affected / exposed	4 / 32 (12.50%)	2 / 64 (3.13%)	17 / 365 (4.66%)
occurrences (all)	4	2	17
Hair colour changes			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	5 / 365 (1.37%)
occurrences (all)	2	0	5
Hyperhidrosis			
subjects affected / exposed	1 / 32 (3.13%)	2 / 64 (3.13%)	17 / 365 (4.66%)
occurrences (all)	1	2	18
Nail dystrophy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Plantar erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1

Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	7 / 32 (21.88%)	14 / 64 (21.88%)	71 / 365 (19.45%)
occurrences (all)	7	14	73
Hypophysitis			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	27 / 365 (7.40%)
occurrences (all)	1	1	28
Hypothyroidism			
subjects affected / exposed	10 / 32 (31.25%)	12 / 64 (18.75%)	84 / 365 (23.01%)
occurrences (all)	11	13	91
Adrenal insufficiency			
subjects affected / exposed	2 / 32 (6.25%)	2 / 64 (3.13%)	18 / 365 (4.93%)
occurrences (all)	2	2	20
Immune-Mediated hyperthyroidism			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Thyroiditis			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	12 / 365 (3.29%)
occurrences (all)	2	0	12
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 32 (6.25%)	9 / 64 (14.06%)	56 / 365 (15.34%)
occurrences (all)	2	11	81
Back pain			
subjects affected / exposed	1 / 32 (3.13%)	4 / 64 (6.25%)	44 / 365 (12.05%)
occurrences (all)	2	5	53
Musculoskeletal pain			
subjects affected / exposed	1 / 32 (3.13%)	3 / 64 (4.69%)	23 / 365 (6.30%)
occurrences (all)	1	3	26
Myalgia			
subjects affected / exposed	2 / 32 (6.25%)	4 / 64 (6.25%)	29 / 365 (7.95%)
occurrences (all)	2	6	34
Pain in extremity			
subjects affected / exposed	6 / 32 (18.75%)	4 / 64 (6.25%)	19 / 365 (5.21%)
occurrences (all)	10	4	23
Haematoma muscle			

subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	1 / 32 (3.13%)	0 / 64 (0.00%)	5 / 365 (1.37%)
occurrences (all)	1	0	5
Limb mass			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	8 / 365 (2.19%)
occurrences (all)	0	0	8
Neck pain			
subjects affected / exposed	1 / 32 (3.13%)	3 / 64 (4.69%)	11 / 365 (3.01%)
occurrences (all)	1	4	11
Pain in jaw			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 32 (12.50%)	7 / 64 (10.94%)	29 / 365 (7.95%)
occurrences (all)	5	9	39
Conjunctivitis			
subjects affected / exposed	1 / 32 (3.13%)	2 / 64 (3.13%)	12 / 365 (3.29%)
occurrences (all)	1	2	13
Infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences (all)	0	0	3
Influenza			
subjects affected / exposed	2 / 32 (6.25%)	0 / 64 (0.00%)	8 / 365 (2.19%)
occurrences (all)	2	0	8
Oral candidiasis			
subjects affected / exposed	1 / 32 (3.13%)	1 / 64 (1.56%)	18 / 365 (4.93%)
occurrences (all)	1	1	18
Oral fungal infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences (all)	0	0	2

Oral herpes			
subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	11 / 365 (3.01%)
occurrences (all)	0	1	11
Paronychia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	4 / 365 (1.10%)
occurrences (all)	0	0	5
Post procedural cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	0 / 365 (0.00%)
occurrences (all)	0	0	0
Tongue fungal infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	1 / 365 (0.27%)
occurrences (all)	0	0	1
Tooth abscess			
subjects affected / exposed	0 / 32 (0.00%)	0 / 64 (0.00%)	2 / 365 (0.55%)
occurrences (all)	0	0	2
Upper respiratory tract infection			
subjects affected / exposed	2 / 32 (6.25%)	3 / 64 (4.69%)	19 / 365 (5.21%)
occurrences (all)	2	3	23
Urinary tract infection			
subjects affected / exposed	3 / 32 (9.38%)	2 / 64 (3.13%)	20 / 365 (5.48%)
occurrences (all)	3	2	23
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	7 / 32 (21.88%)	12 / 64 (18.75%)	87 / 365 (23.84%)
occurrences (all)	13	17	105
Hypokalaemia			
subjects affected / exposed	2 / 32 (6.25%)	9 / 64 (14.06%)	32 / 365 (8.77%)
occurrences (all)	2	12	43
Diabetes mellitus			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	4 / 365 (1.10%)
occurrences (all)	0	2	4
Hyperglycaemia			
subjects affected / exposed	0 / 32 (0.00%)	2 / 64 (3.13%)	17 / 365 (4.66%)
occurrences (all)	0	2	20
Hypocalcaemia			

subjects affected / exposed	0 / 32 (0.00%)	1 / 64 (1.56%)	8 / 365 (2.19%)
occurrences (all)	0	1	11
Hyponatraemia			
subjects affected / exposed	2 / 32 (6.25%)	1 / 64 (1.56%)	15 / 365 (4.11%)
occurrences (all)	2	1	17
Hypophosphataemia			
subjects affected / exposed	0 / 32 (0.00%)	3 / 64 (4.69%)	6 / 365 (1.64%)
occurrences (all)	0	3	10

Non-serious adverse events	Nivolumab + Ipilimumab Acral	Nivolumab + Ipilimumab Other	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	60 / 62 (96.77%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences (all)	0	0	
Hepatic neoplasm			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Malignant neoplasm progression			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	4 / 62 (6.45%)	
occurrences (all)	0	4	
Hot flush			
subjects affected / exposed	0 / 10 (0.00%)	4 / 62 (6.45%)	
occurrences (all)	0	4	
Lymphoedema			
subjects affected / exposed	2 / 10 (20.00%)	0 / 62 (0.00%)	
occurrences (all)	2	0	
Lymphorrhoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	2	0	
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	2 / 10 (20.00%)	15 / 62 (24.19%)	
occurrences (all)	5	16	
Chills			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Fatigue			
subjects affected / exposed	1 / 10 (10.00%)	22 / 62 (35.48%)	
occurrences (all)	1	31	
Influenza like illness			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
Oedema peripheral			
subjects affected / exposed	2 / 10 (20.00%)	5 / 62 (8.06%)	
occurrences (all)	2	5	
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)	18 / 62 (29.03%)	
occurrences (all)	10	22	
Gait disturbance			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
Hyperthermia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Malaise			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	5	0	
Non-Cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences (all)	0	0	
Reproductive system and breast disorders			
Rectocele			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Vaginal haemorrhage			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 62 (1.61%) 1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 10 (20.00%)	16 / 62 (25.81%)	
occurrences (all)	3	20	
Dyspnoea			
subjects affected / exposed	2 / 10 (20.00%)	8 / 62 (12.90%)	
occurrences (all)	2	9	
Epistaxis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Haemoptysis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	5 / 62 (8.06%)	
occurrences (all)	1	6	
Pleural effusion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Pulmonary embolism			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
Pulmonary pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 10 (0.00%)	4 / 62 (6.45%)	
occurrences (all)	0	4	
Anxiety			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Depression			

subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	10 / 62 (16.13%)	
occurrences (all)	1	14	
Amylase increased			
subjects affected / exposed	0 / 10 (0.00%)	4 / 62 (6.45%)	
occurrences (all)	0	6	
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	7 / 62 (11.29%)	
occurrences (all)	1	10	
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	3	
Lipase increased			
subjects affected / exposed	0 / 10 (0.00%)	9 / 62 (14.52%)	
occurrences (all)	0	11	
Weight decreased			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	2	5	
Blood bilirubin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences (all)	0	0	
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Blood potassium decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
Blood thyroid stimulating hormone increased			

subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Blood uric acid increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
C-Reactive protein increased			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
Gamma-Glutamyltransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Haemoglobin decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	2	
Hepatic enzyme increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Liver function test increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Neutrophil count decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Thyroxine increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Transaminases increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	2	
Cardiac disorders			

Atrial tachycardia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 62 (0.00%) 0	
Tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 62 (1.61%) 1	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 4	10 / 62 (16.13%) 12	
Dizziness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	6 / 62 (9.68%) 6	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 62 (0.00%) 0	
Somnolence subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 62 (1.61%) 1	
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 5	15 / 62 (24.19%) 20	
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 62 (1.61%) 1	
Lymphopenia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 62 (0.00%) 0	
Eye disorders			
Eyelash discolouration subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 62 (0.00%) 0	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	8 / 62 (12.90%) 13	

Abdominal pain upper		
subjects affected / exposed	2 / 10 (20.00%)	1 / 62 (1.61%)
occurrences (all)	2	1
Constipation		
subjects affected / exposed	1 / 10 (10.00%)	9 / 62 (14.52%)
occurrences (all)	1	11
Diarrhoea		
subjects affected / exposed	5 / 10 (50.00%)	25 / 62 (40.32%)
occurrences (all)	8	42
Dry mouth		
subjects affected / exposed	1 / 10 (10.00%)	7 / 62 (11.29%)
occurrences (all)	1	8
Nausea		
subjects affected / exposed	5 / 10 (50.00%)	15 / 62 (24.19%)
occurrences (all)	6	24
Vomiting		
subjects affected / exposed	2 / 10 (20.00%)	10 / 62 (16.13%)
occurrences (all)	4	11
Abdominal distension		
subjects affected / exposed	2 / 10 (20.00%)	2 / 62 (3.23%)
occurrences (all)	2	2
Colitis		
subjects affected / exposed	0 / 10 (0.00%)	5 / 62 (8.06%)
occurrences (all)	0	6
Dyspepsia		
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)
occurrences (all)	0	4
Dysphagia		
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)
occurrences (all)	0	1
Haematemesis		
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)
occurrences (all)	1	0
Haemorrhoidal haemorrhage		
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)
occurrences (all)	2	0

Mouth ulceration subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 62 (0.00%) 0	
Stomatitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	2 / 62 (3.23%) 2	
Hepatobiliary disorders Hepatocellular injury subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	3 / 62 (4.84%) 4	
Hypertransaminasaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 62 (0.00%) 0	
Liver tenderness subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 62 (0.00%) 0	
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all)	4 / 10 (40.00%) 8	16 / 62 (25.81%) 19	
Rash subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 3	9 / 62 (14.52%) 10	
Rash macular subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	3 / 62 (4.84%) 5	
Rash maculo-papular subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 3	6 / 62 (9.68%) 7	
Rash pruritic subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 62 (0.00%) 0	
Vitiligo subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	9 / 62 (14.52%) 11	
Acne			

subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Alopecia			
subjects affected / exposed	2 / 10 (20.00%)	2 / 62 (3.23%)	
occurrences (all)	2	2	
Dry skin			
subjects affected / exposed	2 / 10 (20.00%)	2 / 62 (3.23%)	
occurrences (all)	3	2	
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Erythema			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	1	3	
Hair colour changes			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Hyperhidrosis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
Nail dystrophy			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Plantar erythema			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 10 (0.00%)	8 / 62 (12.90%)	
occurrences (all)	0	10	
Hypophysitis			

subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Hypothyroidism			
subjects affected / exposed	2 / 10 (20.00%)	16 / 62 (25.81%)	
occurrences (all)	2	19	
Adrenal insufficiency			
subjects affected / exposed	2 / 10 (20.00%)	1 / 62 (1.61%)	
occurrences (all)	2	1	
Immune-Mediated hyperthyroidism			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Thyroiditis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 62 (1.61%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 10 (10.00%)	11 / 62 (17.74%)	
occurrences (all)	5	11	
Back pain			
subjects affected / exposed	1 / 10 (10.00%)	4 / 62 (6.45%)	
occurrences (all)	1	4	
Musculoskeletal pain			
subjects affected / exposed	2 / 10 (20.00%)	4 / 62 (6.45%)	
occurrences (all)	2	5	
Myalgia			
subjects affected / exposed	0 / 10 (0.00%)	6 / 62 (9.68%)	
occurrences (all)	0	7	
Pain in extremity			
subjects affected / exposed	3 / 10 (30.00%)	4 / 62 (6.45%)	
occurrences (all)	5	6	
Haematoma muscle			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Joint swelling			

subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
Limb mass			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Neck pain			
subjects affected / exposed	1 / 10 (10.00%)	4 / 62 (6.45%)	
occurrences (all)	1	4	
Pain in jaw			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	2 / 10 (20.00%)	10 / 62 (16.13%)	
occurrences (all)	4	13	
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Influenza			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	
Oral candidiasis			
subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	3	
Oral fungal infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Oral herpes			
subjects affected / exposed	1 / 10 (10.00%)	1 / 62 (1.61%)	
occurrences (all)	1	1	

Paronychia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Post procedural cellulitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	3	0	
Tongue fungal infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	1	0	
Tooth abscess			
subjects affected / exposed	1 / 10 (10.00%)	0 / 62 (0.00%)	
occurrences (all)	2	0	
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	2 / 62 (3.23%)	
occurrences (all)	0	2	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 10 (10.00%)	13 / 62 (20.97%)	
occurrences (all)	1	14	
Hypokalaemia			
subjects affected / exposed	1 / 10 (10.00%)	3 / 62 (4.84%)	
occurrences (all)	1	6	
Diabetes mellitus			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	3	
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 62 (0.00%)	
occurrences (all)	0	0	
Hypocalcaemia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	2	
Hyponatraemia			

subjects affected / exposed	0 / 10 (0.00%)	3 / 62 (4.84%)	
occurrences (all)	0	5	
Hypophosphataemia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 62 (3.23%)	
occurrences (all)	1	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 January 2016	Exclusion Criteria Update
05 February 2016	Exclusion Criterion Update
25 May 2016	Study Treatment Dose Update
03 August 2016	Management Algorithms for Immuno-Oncology Agents Update
19 August 2016	Adverse Event Management Algorithms Update
31 July 2018	Follow-up Phase Timeline Update

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The Nivolumab monotherapy dose in Part II is changed to 240 mg flat dose for those subjects who enrolled after the implementation of Amendment 04

Notes: